Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Fosfocreatine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MVD | P53602 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fosfocreatine SCHEMBL1640494 | 1.00 | MVD (0.38) | MVD | |
| Fosfocreatine SCHEMBL31181876 | 0.98 | MVD (0.37) | MVD | |
| Fosfocreatine SCHEMBL30930087 | 0.98 | MVD (0.37) | MVD | |
| Fosfocreatine SCHEMBL29749874 | 0.86 | MVD (0.40) | MVD | |
| Fosfocreatine SCHEMBL612834 | 0.86 | — | — | |
| Fosfocreatine SCHEMBL9319928 | 0.82 | — | — | |
| Fosfocreatine SCHEMBL3026727 | 0.82 | — | — | |
| Fosfocreatine SCHEMBL24116748 | 0.81 | MVD (0.44) | MVD | |
| Fosfocreatine SCHEMBL2124030 | 0.81 | MVD (0.44) | MVD | |
| Fosfocreatine SCHEMBL65425 | 0.81 | MVD (0.44) | MVD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12543767-B2 | Oral supplements containing enriched phenolic compound extracts combined with organic acid sodium salts, creatines and/or creatine salts | PHENOLICS, LLC | 2026-02-10 | — | — | US | claimed |
| US-20220338519-A1 | ORAL SUPPLEMENTS CONTAINING ENRICHED PHENOLIC COMPOUND EXTRACTS COMBINED WITH ORGANIC ACID SODIUM SALTS, CREATINES AND/OR CREATINE SALTS | PHENOLICS, LLC (US) | 2022-10-27 | — | — | US | claimed |
| US-12543767-B2 | Oral supplements containing enriched phenolic compound extracts combined with organic acid sodium salts, creatines and/or creatine salts | PHENOLICS, LLC | 2026-02-10 | — | — | US | disclosed |
| WO-2025227157-A1 | MODIFIED CELLS AND USES THEREOF | UNIVERSITY OF MIAMI (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12187681-B2 | Ion channel antagonists/blockers and uses thereof | SHANGHAI EAST HOSPITAL (CN) | 2025-01-07 | — | — | US | disclosed |
| US-20230015875-A1 | Ion Channel Antagonists/Blockers and Uses Thereof | SHANGHAI EAST HOSPITAL (CN) | 2023-01-19 | — | — | US | disclosed |
| US-20220338519-A1 | ORAL SUPPLEMENTS CONTAINING ENRICHED PHENOLIC COMPOUND EXTRACTS COMBINED WITH ORGANIC ACID SODIUM SALTS, CREATINES AND/OR CREATINE SALTS | PHENOLICS, LLC (US) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12543767-B2 | Oral supplements containing enriched phenolic compound extracts combined with organic acid sodium salts, creatines and/or creatine salts | SLC22A8, SLC8B1, MCU | MVD 1763/4885 |
| US-20230015875-A1 | Ion Channel Antagonists/Blockers and Uses Thereof | CACNA1F, CACNA1S, CACNA1D | MVD 904/4885 |
| US-12187681-B2 | Ion channel antagonists/blockers and uses thereof | CACNA1F, CACNA1S, CACNA1D | MVD 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.